Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.56 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2797701 | 0.97 | ALDH1A1 (0.52) | GPR119PTPN2PTPN1PTPN6ALDH1A1 | |
| SCHEMBL8310166 | 0.88 | ALDH1A1 (0.65) | GPR119PTPN2PTPN1PTPN6ALDH1A1 | |
| SCHEMBL3457225 | 0.85 | TEAD1 (0.61) | GPR119PTPN2PTPN1PTPN6MAPT | |
| SCHEMBL7381166 | 0.84 | ALDH1A1 (0.69) | GPR119ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL2793493 | 0.84 | GPR119 (0.57) | GPR119PTPN2PTPN1PTPN6ALDH1A1 | |
| SCHEMBL1857852 | 0.83 | GPR119 (0.53) | GPR119ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL652849 | 0.83 | HTT (0.57) | GPR119ALDH1A1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL5013239 | 0.83 | ALDH1A1 (0.51) | GPR119PTPN2PTPN1PTPN6ALDH1A1 | |
| SCHEMBL4139902 | 0.83 | DNMT3A (0.56) | GPR119PTPN2PTPN1PTPN6ALDH1A1 | |
| SCHEMBL616004 | 0.83 | STS (0.60) | GPR119ALDH1A1SMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076762-A1 | Novel 4-Aminopiperidine Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-03-27 | — | — | US | disclosed |
| WO-2006056930-A2 | NOVEL 4 -AMINOPIPERIDINE DERIVATIVES AS PLASMEPSIN II INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076762-A1 | Novel 4-Aminopiperidine Derivatives | METAP1, DNPEP, PEPD | GPR119 1238/4885PTPN2 1810/4885PTPN1 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.